Thank you ohm, I remember you stating that with leronlimab CD8 increases.....and remember from the videos on the CytoDyn website that leronlimab binds a specific spot on the CCR5 while still allowing functionality whereas other CCR5 antagonists are ‘deep buried’ and block all entry into the receptor.

I know some conversations I had on SA where this was a concern if leronlimab would have success in cancer (like maraviroc showed) due to not blocking the entire receptor? Time will tell, but based on preclinical comparisons things look promising.